Top HIV scientist says he wouldn't count on a vaccine for coronavirus soon

Published 2020-05-20, 05:12 p/m
© Reuters. FILE PHOTO: An illustration, created at the Centers for Disease Control and Prevention (CDC), depicts the 2019 Novel Coronavirus

By Alessandra Galloni

(Reuters) - A top U.S. scientist said on Wednesday that governments should not count on a successful vaccine against COVID-19 being developed anytime soon when deciding whether to ease restrictions imposed to curb the pandemic.

William Haseltine, a groundbreaking researcher of cancer, HIV/AIDS and human genome projects, said the better approach now is to manage the disease through careful tracing of infections and strict isolation measures whenever it starts spreading.

While a COVID-19 vaccine could be developed, he said, "I wouldn't count on it."

Vaccines developed previously for other types of coronavirus had failed to protect mucous membranes in the nose where the virus typically enters the body, he said.

Even without an effective treatment or vaccine, the virus can be controlled by identifying infections, finding people who have been exposed and isolating them, he said. He urged people to wear masks, wash hands, clean surfaces and keep a distance.

He said China and some other Asian countries used that strategy successfully, while the United States and other countries did not do enough to "forcibly isolate" all who were exposed to the virus.

China, South Korea and Taiwan have done the best at curbing infections, he said, while the United States, Russia and Brazil have done the worst.

Tests on animals of experimental COVID-19 vaccines had been able to reduce the viral load in organs like lungs although the infections remained, he said.

For treatment, patients have been getting antibody-rich plasma donated by people who recovered from COVID-19, and drugmakers are at work producing refined and concentrated versions of that serum.

© Reuters. FILE PHOTO: An illustration, created at the Centers for Disease Control and Prevention (CDC), depicts the 2019 Novel Coronavirus

Known as hyperimmune globulin, those products are "where the first real treatments are going to be," he said, predicting success also with research into monoclonal antibodies that home in on and neutralize the ability of the virus to enter human cells.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.